This campaign focused on highlighting Repatha's efficacy in significantly lowering LDL cholesterol in patients at increased cardiovascular risk. Developed for HCPs, the work emphasized the treatment's ability to deliver substantial cholesterol reductions, positioning Repatha as an important option for patients who need additional LDL cholesterol control.
